Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.61 |
| ▸ | MC5R | P33032 | 8/20 | 0.61 |
| ▸ | MC3R | P41968 | 8/20 | 0.61 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3795459 | 1.00 | MC4R (0.61) | MC4RMC5RMC3RLIMK2MAOA | |
| SCHEMBL2584582 | 0.93 | LIMK2 (0.56) | MC4RMC5RMC3RLIMK2REN | |
| SCHEMBL21628078 | 0.91 | REN (0.56) | MC4RMC5RMC3RREN | |
| SCHEMBL1023411 | 0.85 | CARM1 (0.55) | MC4RMC3RLIMK2REN | |
| SCHEMBL8329778 | 0.85 | MC4R (0.51) | MC4RMC5RMC3R | |
| SCHEMBL3884654 | 0.85 | MC4R (0.48) | MC4RMC5RMC3R | |
| SCHEMBL16333819 | 0.84 | REN (0.54) | MC4RMC5RMC3RREN | |
| SCHEMBL13723381 | 0.84 | REN (0.54) | MC4RMC5RMC3RREN | |
| Hydrochloric Acid SCHEMBL570912 | 0.84 | CARM1 (0.53) | MC4RMC3RLIMK2REN | |
| SCHEMBL15546987 | 0.83 | CNR2 (0.64) | LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY | 2024-06-27 | — | — | US | disclosed |
| EP-4313051-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | Virginia Commonwealth University (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022212471-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208984-A1 | BIVALENT LIGANDS TO UNDERSTAND DIMERIZATION OF THE MU OPIOID RECEPTOR AND THE CHEMOKINE RECEPTOR CCR5 IN NEUROLOGICAL DISORDERS | OPRM1, OPRK1, CCR5 | MC4R 339/4885MC5R 305/4885MC3R 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.